364 related articles for article (PubMed ID: 22987267)
41. Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies.
Stanzani M; Vianelli N; Cavo M; Maritati A; Morotti M; Lewis RE
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28607011
[TBL] [Abstract][Full Text] [Related]
42. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.
Wingard JR; Kubilis P; Lee L; Yee G; White M; Walshe L; Bowden R; Anaissie E; Hiemenz J; Lister J
Clin Infect Dis; 1999 Dec; 29(6):1402-7. PubMed ID: 10585786
[TBL] [Abstract][Full Text] [Related]
43. [Safety of liposomal amphotericin B in patients with high risk of nephrotoxicity].
González E; Rada MA; Lumbreras C; Ramos JT; Aguado JM
Enferm Infecc Microbiol Clin; 2000 Apr; 18(4):162-4. PubMed ID: 10932392
[TBL] [Abstract][Full Text] [Related]
44. [Analysis of the use of liposomal amphotericin B].
González Martínez M; Mariño Martínez C; Baldominos Utrilla G; Fernández Martínez MN
Rev Iberoam Micol; 2014; 31(2):109-13. PubMed ID: 23711815
[TBL] [Abstract][Full Text] [Related]
45. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
[TBL] [Abstract][Full Text] [Related]
46. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
Bowden R; Chandrasekar P; White MH; Li X; Pietrelli L; Gurwith M; van Burik JA; Laverdiere M; Safrin S; Wingard JR
Clin Infect Dis; 2002 Aug; 35(4):359-66. PubMed ID: 12145716
[TBL] [Abstract][Full Text] [Related]
47. Proteinuria lowers the risk of amphotericin B-associated hypokalaemia.
Mohan S; Ahmed S; Alimohammadi B; Jaitly M; Cheng JT; Pogue VA
J Antimicrob Chemother; 2007 Sep; 60(3):690-3. PubMed ID: 17597057
[TBL] [Abstract][Full Text] [Related]
48. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
[TBL] [Abstract][Full Text] [Related]
49. Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan.
Takazono T; Tashiro M; Ota Y; Obata Y; Wakamura T; Miyazaki T; Nishino T; Izumikawa K
Sci Rep; 2020 Sep; 10(1):15033. PubMed ID: 32929112
[TBL] [Abstract][Full Text] [Related]
50. A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity.
Karimzadeh I; Khalili H; Sagheb MM; Farsaei S
Expert Opin Drug Metab Toxicol; 2015; 11(9):1345-55. PubMed ID: 26050706
[TBL] [Abstract][Full Text] [Related]
51. Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection.
Bodhe PV; Kotwani RN; Kirodian BG; Kshirsagar NA; Pandya SK
J Assoc Physicians India; 2002 May; 50(5):662-70. PubMed ID: 12186120
[TBL] [Abstract][Full Text] [Related]
52. Must we really fear toxicity of conventional amphotericin B in oncological patients?
Mayer J; Doubek M; Vorlìcek J
Support Care Cancer; 1999 Jan; 7(1):51-5. PubMed ID: 9926976
[TBL] [Abstract][Full Text] [Related]
53. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients.
Brienza N; Malcangi V; Dalfino L; Trerotoli P; Guagliardi C; Bortone D; Faconda G; Ribezzi M; Ancona G; Bruno F; Fiore T
Crit Care Med; 2006 Mar; 34(3):707-14. PubMed ID: 16505657
[TBL] [Abstract][Full Text] [Related]
54. Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.
Azoulay E; Timsit JF; Lautrette A; Legriel S; Max A; Ruckly S; Misset B; Cohen Y; Wolff M
PLoS One; 2017; 12(5):e0177093. PubMed ID: 28531175
[TBL] [Abstract][Full Text] [Related]
55. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
56. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.
Imhof A; Walter RB; Schaffner A
Clin Infect Dis; 2003 Apr; 36(8):943-51. PubMed ID: 12684904
[TBL] [Abstract][Full Text] [Related]
57. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
58. One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment.
Bagshaw SM; Mortis G; Doig CJ; Godinez-Luna T; Fick GH; Laupland KB
Am J Kidney Dis; 2006 Sep; 48(3):402-9. PubMed ID: 16931213
[TBL] [Abstract][Full Text] [Related]
59. Treatment of mycotic infections after haemopoietic progenitor cell transplantation with liposomal amphotericin-B.
Krüger WH; Kröger N; Rüssmann B; Renges H; Kabisch H; Zander AR
Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S10-3. PubMed ID: 9916623
[TBL] [Abstract][Full Text] [Related]
60. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH;
Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
